selected scholarly activity
-
chapters
- Challenges and Strategies in the Analysis of Multiple Events in Oncology. Cancer Drug Discovery and Development. 191-199. 2005
- The Role of Bisphosphonates in Bone Metastasis. Cancer Metastasis - Biology and Treatment. 277-301. 2004
- Marginal Analysis of Point Processes with Competing Risks. Handbook of Statistics. 349-361. 2003
- Characterization of Cross-Related Antigens of Human Milk Fat Globule Membrane and Breast Tumors Detected by a New Monoclonal Antibody Panel. 3-19. 1987
- MUCIN 1 in Prostate Cancer. 125-138.
-
conferences
- Using control charts to assess the consistency of breast cancer grading in 1,453 resections. Virchows Archiv. S199-S199. 2018
- Virtual Reality using Gesture Recognition for Deck Operation Training. Oceans Conference Record (IEEE). 2017
- NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.. Journal of Clinical Oncology. 3-3. 2016
- Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA. International Journal of Radiation Oncology Biology Physics. 3-3. 2016
- Impact of radiotherapy duration on outcomes in patients with esophageal cancer treated with definitive concurrent radiotherapy and chemotherapy on RTOG trials 8501 and 9405.. Journal of Clinical Oncology. 119-119. 2015
- THE IMPACT OF LAPAROSCOPIC BARIATRIC PROCEDURES ON CHRONIC INFLAMMATION AND BONE METABOLISM IN PATIENTS TREATED DUE TO MORBID OBESITY IN THE 2ND DEPARTMENT OF SURGERY UJ CM. Obesity Surgery. 1358-1358. 2014
- Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab.. Journal of Clinical Oncology. 2013
- Vaccination with autologous dendritic cells pulsed with a MUC1 glycopeptide: a phase I/II study in castrate resistant non-metastatic prostate cancer patients. Cytotherapy. S39-S39. 2013
- Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab.. Journal of Clinical Oncology. 540-540. 2013
- Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients. Cancer Research. A16-A16. 2012
- 536 oral RTOG 9601: SALVAGE RT & ANTI-ANDROGEN THERAPY IN PROSTATE CANCER PATIENTS WITH ELEVATED PSA AFTER SURGERY. Radiotherapy and Oncology. S219-S219. 2011
- Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels. Journal of Clinical Oncology. 2011
- Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels. International Journal of Radiation Oncology Biology Physics. S27-S27. 2010
- Low Dose Upper Abdominal Radiation Therapy (LD-UART) Potentiates Gemcitabine in Patients with Advanced, Unresectable Pancreatic Cancer (PC): Final Results from a Phase II Multi-Institutional Study. International Journal of Radiation Oncology Biology Physics. S103-S103. 2010
- Natural History of Metastatic Bone Disease in Breast Cancer Based on Site of Bone Lesions. Bone. S329-S329. 2010
- Superior value of [18F]6-FDOPA PET/CT in staging of neuroendocrine tumors. Journal of Nuclear Medicine. 2010
- A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer. Journal of Clinical Oncology. 2009
- EFFECTS OF ZOLEDRONIC ACID (ZOL) ON SURVIVAL IN PATIENTS WITH METASTATIC BONE DISEASE AND HIGH BONE TURNOVER: RESULTS FROM A META-ANALYSIS. Annals of Oncology. 276-276. 2008
- RISK FACTORS FOR SKELETAL-RELATED EVENT (SRES) IN ZOLEDRONIC ACID-TREATED PATIENTS WITH BONE METASTASES (METS) FROM NON-SMALL CELL LUNG CANCER (NSCLC). Annals of Oncology. 275-275. 2008
- Radiation Therapy (RT) as a Chemopotentiator of Gemcitabine (G) in Patients with Advanced Pancreatic Cancer: A Multi-institutional Phase II Study. International Journal of Radiation Oncology Biology Physics. S258-S259. 2008
- THE PROGNOSTIC VALUE OF PAIN SCORES FOR CLINICAL OUTCOMES IN ADVANCED BREAST CANCER (BC), PROSTATE CANCER (PC), AND OTHER SOLID TUMORS (OST). Annals of Oncology. 255-255. 2008
- Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD): Survival in patients with high bone turnover. Journal of Clinical Oncology. 20562-20562. 2008
- Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP. Journal of Clinical Oncology. 19003-19003. 2008
- The prognostic value of pain scores for clinical outcomes in advanced breast cancer and prostate cancer. Journal of Clinical Oncology. 22120-22120. 2008
- EFFECTS OF ZOLEDRONIC ACID DOSE AND INFUSION RATE ON PHARMACOKINETICS, PHARMACODYNAMICS, AND RENAL FUNCTION IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER. Investigative Urology. 181-181. 2008
- Skeletal-related event (SRE) history, bone metastasis location and number affect SRE risk and patient survival in metastatic breast cancer. European Journal of Cancer, Supplement. 174-174. 2008
- Disease and treatment parameters significantly affect skeletal complications and survival in metastatic breast cancer. Bone. S61-S61. 2008
- OC4. Number and sites of bone lesions and history of skeletal-related events (SREs): Do these parameters correspond with skeletal morbidity and mortality in patients with bone metastases (mets) from hormone-refractory prostate cancer (HRPC)?. Cancer Treatment Reviews. 50-51. 2008
- P79. N-Telopeptide of type I collagen (NTX) levels and prognosis in patients with bone metastases from non-small cell lung cancer (NSCLC) receiving zoledronic acid (ZOL) or placebo. Cancer Treatment Reviews. 42-42. 2008
- P81. Meta-analysis of effects of zoledronic acid (ZOL) on survival in patients with metastatic bone disease (MBD) and high bone turnover. Cancer Treatment Reviews. 43-43. 2008
- Natural history of skeletal complications in patients receiving chemotherapy for breast cancer metastatic to bone. Breast Cancer Research and Treatment. S103-S103. 2007
- Patients' disease and treatment parameters significantly affect survival in metastatic breast cancer. Breast Cancer Research and Treatment. S102-S103. 2007
- Survival in breast cancer patients with bone metastases and reductions in markers of bone resorption during zoledronic acid treatment.. Breast Cancer Research and Treatment. S39-S39. 2007
- 304 ORAL Early normalization of elevated baseline bone resorption marker levels by zoledronic acid and improved survival in patients with bone metastases from solid tumors. European Journal of Cancer, Supplement. 58-58. 2007
- 515 POSTER Zoledronic Acid (ZOL) treatment may improve survival in patients with lung cancer and high baseline N-telopeptide levels: a multivariate Cox regression analysis. European Journal of Cancer, Supplement. 94-94. 2007
- D5-07: Survival and zoledronic acid-induced normalization of bone marker levels in patients with non-small cell lung cancer. Journal of Thoracic Oncology. S406-S406. 2007
- PD6-3-7: Bone metastases from non-small cell lung cancer (NSCLC) result in meaningful skeletal morbidity within a patient’s lifetime. Journal of Thoracic Oncology. S434-S434. 2007
- Normalization of bone markers and improved survival during zoledronic acid therapy. Journal of Clinical Oncology. 2007
- Multistate Analysis of Skeletal Events in Patients with Bone Metastases. Clinical Cancer Research. 6264s-6269s. 2006
- Gastrointestinal side effects can reduce compliance with oral bisphosphonate therapy in cancer patients. European Journal of Oncology Nursing. 226-226. 2006
- A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts.. Journal of Clinical Oncology. 153S-153S. 2006
- Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: Stratified by baseline bone alkaline phosphatase (BALP).. Journal of Clinical Oncology. 421S-421S. 2006
- Surgeon variability in treating nonpalpable breast cancer. Are surgical oncologists different?. Annals of Surgical Oncology. 84-85. 2006
- A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (PTS) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH PTS. Annals of Oncology. 122-122. 2006
- Prognostic significance of persistently elevated N-telopeptide levels in patients with bone metastases from solid tumors. Annals of Oncology. 254-255. 2006
- Zoledronic acid may improve survival in lung cancer patients with high baseline bone marker levels. Annals of Oncology. 221-221. 2006
- Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM).. Blood. 5015-5015. 2005
- Breast cancer patients with persistently increased bone resorption. European Journal of Cancer, Supplement. 121-121. 2005
- Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid. Journal of Clinical Oncology. 4925-4935. 2005
- Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome.. Journal of Clinical Oncology. 11S-11S. 2005
- The effect of zoledronic acid (Zol) dose and infusion rate on pharmacolkinetics (PK), pharmacodynamics (PD), and renal function in patients (pts) with multiple myeloma (MM) or prostate cancer (PC) and bone metastases.. Journal of Clinical Oncology. 154S-154S. 2005
- Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer.. Breast Cancer Research and Treatment. S129-S129. 2005
- Clinical Endpoints for Assessing Bisphosphonate Efficacy in the Prevention of Skeletal Complications of Bone Metastases. European Urology Open Science. 34-39. 2004
- Survival-adjusted multiple event analysis of skeletal complications front bone metastases: A comprehensive analysis of treatment benefit. Journal of Bone and Mineral Research. 1595-1595. 2004
- The predictive value of bone resorption and formation markers in patients with prostate cancer metastatic to bone. Journal of Bone and Mineral Research. 1596-1596. 2004
- The prognostic significance of biochemical markers of bone metabolism in patients with bone metastases from solid tumors other than breast and prostate cancer. Journal of Bone and Mineral Research. 1596-1596. 2004
- A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer.. Journal of Clinical Oncology. 344S-344S. 2004
- A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 222S-222S. 2004
- Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 204S-204S. 2004
- Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 3037-3037. 2004
- Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 3037-3037. 2004
- Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis.. Journal of Clinical Oncology. 743S-743S. 2004
- Gastrointestinal adverse events can reduce compliance with oral bisphosphonate therapy and result in early study termination. Bone. S80-S81. 2004
- Safety and convenience of bisphosphonate infusions. Bone. S82-S83. 2004
- Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Bone. S88-S88. 2004
- Zoledronic acid reduces the risk of skeletal complications in patients with malignant bone disease: evidence from 3 different multiple event analysis models. Annals of Oncology. 225-225. 2004
- Zoledronic acid reduces the survival-adjusted cumulative incidence of radiotherapy to bone in patients with bone metastases from breast or prostate cancer. Annals of Oncology. 124-124. 2004
- A phase II trial of the proteosome inhibitor PS-341 (Bortezomib; Velcade)in patients with metastatic colorectal cancer.. Clinical Cancer Research. 6201S-6201S. 2003
- The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function. Journal of Clinical Pharmacology. 154-162. 2003
- Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis.. Breast Cancer Research and Treatment. S95-S95. 2002
- Phase II study of OSI-774 in patients with metastatic colorectal cancer. European Journal of Cancer. S57-S57. 2002
- Effect of renal function on the pharmacokinetics (PK), pharmacodynamics (PD), and safety of zoledronic acid in cancer patients with bone metastases.. Blood. 167A-167A. 2001
- Initial results of part 2 of a phase I/II pharmacokinetics (PK), pharmacodynamic (PD), and biological activity study of ZD1839 (Iressa (TM)): NCICCTG IND.122.. Clinical Cancer Research. 3761S-3761S. 2001
- Phase III study of zoledronic acid versus pamidronate in patients with metastatic bone lesions due to breast cancer or multiple myeloma: Preliminary results.. Annals of Oncology. 153-153. 2000
- BREAST-TUMOR RADIOIMMUNODETECTION WITH A IN-111-LABELED MONOCLONAL-ANTIBODY (MA5) AGAINST A MUCIN-LIKE ANTIGEN. Cancer Research. S927-S931. 1990
- PATTERNS OF ANTIGEN DISTRIBUTION IN HUMAN CARCINOMAS. Cancer Research. S880-S884. 1990
- MUCIN-LIKE GLYCOPROTEIN ANTIGENS ARE HETEROGENEOUSLY EXPRESSED BY NORMAL SECRETORY AND BREAST-CARCINOMA CELLS. The FASEB Journal. A1470-A1470. 1988
- HETEROGENEOUS EXPRESSION OF MUCIN-LIKE GLYCOPROTEIN ANTIGENS BY NORMAL SECRETORY AND BREAST-CARCINOMA CELLS. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 394-394. 1988
- RELATED ANTIGENS OF SECRETORY AND MALIGNANT BREAST CELLS - CHARACTERIZATION AND CLINICAL UTILITY. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 394-394. 1988
- CHARACTERIZATION OF CROSS-RELATED ANTIGENS OF BREAST-TUMORS AND MILK-FAT GLOBULE MEMBRANES (MFGM). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 358-358. 1987
- A DOUBLE ANTIBODY-RADIOIMMUNOASSAY (RIA) FOR MONITORING METASTATIC BREAST-CANCER. Breast Cancer Research and Treatment. 95-95. 1987
- DOUBLE ANTIBODY RIA IN CONJUNCTION WITH IMMUNOBLOTTING FOR THE SPECIFIC DETECTION OF A SERUM BREAST-TUMOR MARKER. Journal of Cellular Biochemistry. 122-122. 1987
- RADIOIMMUNOLOCALIZATION STUDIES IN PATIENTS WITH METASTATIC BREAST-CANCER USING INDIUM-111-LABELED MA5 MOUSE MONOCLONAL-ANTIBODIES DIRECTED AT THE EPITHELIAL MEMBRANE ANTIGEN COMPLEX (EMAC). Breast Cancer Research and Treatment. 97-97. 1987
- THE PROGNOSTIC VALUE OF IMMUNO-STAINING WITH MA5 MONOCLONAL-ANTIBODY IN BREAST-CANCER (BC). Laboratory Investigation. A27-A27. 1987
- IDENTIFICATION OF ANTIGENIC DETERMINANTS RECOGNIZED BY A MONOCLONAL-ANTIBODY PANEL PREPARED VERSUS BREAST-TUMOR MEMBRANES. Breast Cancer Research and Treatment. 84-84. 1986
- PHASE-I-II TRIAL OF DEOXYCOFORMYCIN (DCF) IN T-CELL MALIGNANCIES. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 328-328. 1980
-
journal articles
- Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.. Journal of Clinical Oncology. 42:320-320. 2024
- Correction: What is your count? An observational study of lymph node counting in 2,028 colorectal cancer resections. PLoS ONE. 19:e0299858-e0299858. 2024
- Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer. Frontiers in Microbiology. 15:1325558. 2024
- What is your count? An observational study of lymph node counting in 2,028 colorectal cancer resections. PLoS ONE. 19:e0295209-e0295209. 2024
- PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. Journal of Experimental and Clinical Cancer Research. 42:2. 2023
- Physician and Surgeon Communication Assessed via the Pathology Requisition in a Regional Laboratory Over Ten Years. Cureus. 14:e27714. 2022
- Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels. Cancers. 14:2805-2805. 2022
- AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma. Biomedicines. 10:362-362. 2022
- Pathologist workload, work distribution and significant absences or departures at a regional hospital laboratory. PLoS ONE. 17:e0265905-e0265905. 2022
- Insights of RKIP-Derived Suppression of Prostate Cancer. Cancers. 13:6388-6388. 2021
- Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease. iScience. 24:103219-103219. 2021
- Stability of diagnostic rate in a cohort of 38,813 colorectal polyp specimens and implications for histomorphology and statistical process control. Scientific Reports. 11:16942. 2021
- Application of Next Generation Quality/Statistical Process Control and Expert-Led Case Review to Increase the Consistency of Diagnostic Rates in Precancerous Colorectal Polyps. Quality Management in Health Care. 30:176-183. 2021
- Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. Molecular Therapy - Oncolytics. 20:306-324. 2021
- Effective Prediction of Prostate Cancer Recurrence through the IQGAP1 Network. Cancers. 13:430-430. 2021
- Evolution of anatomic pathology workload from 2011 to 2019 assessed in a regional hospital laboratory via 574,093 pathology reports. PLoS ONE. 16:e0253876-e0253876. 2021
- Tumour vasculature: Friend or foe of oncolytic viruses?. Cytokine and Growth Factor Reviews. 56:69-82. 2020
- Construction of a Novel Multigene Panel Potently Predicting Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma. Cancers. 12:3471-3471. 2020
- Contactin 1: An Important and Emerging Oncogenic Protein Promoting Cancer Progression and Metastasis. Genes. 11:874-874. 2020
- Immunohistochemistry Use by Diagnostic Category and Pathologist in 4477 Prostate Core Biopsy Sets Assessed at Two Hospitals. Applied Immunohistochemistry and Molecular Morphology. 28:259-266. 2020
- Variation in breast cancer grading in 1,636 resections assessed using control charts and in silico kappa. PLoS ONE. 15:e0242656-e0242656. 2020
- Assessment of biochemical recurrence of prostate cancer (Review). International Journal of Oncology. 55:1194-1212. 2019
- The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer. Cancers. 11:1028-1028. 2019
- A241 APPLICATION OF NEXT GENERATION QUALITY AND EXPERT-LED CASE REVIEW TO INCREASE THE CONSISTENCY OF SESSILE SERRATED ADENOMA DIAGNOSTIC RATES: A CANADIAN TERTIARY-CARE CENTRE EXPERIENCE. Journal of the Canadian Association of Gastroenterology. 2:472-473. 2019
- Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer. Clinical Cancer Research. 25:1624-1638. 2019
- Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence. Molecular Oncology. 12:1559-1578. 2018
- Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development. Translational Oncology. 11:1012-1022. 2018
- Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer. Molecular Therapy - Methods and Clinical Development. 9:181-191. 2018
- Cost-effective, personalized, 3D-printed liver model for preoperative planning before laparoscopic liver hemihepatectomy for colorectal cancer metastases. International Journal of Computer Assisted Radiology and Surgery. 12:2047-2054. 2017
- Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression. Neoplasia. 19:857-867. 2017
- Laparoscopic uncinate process first pancreatoduodenectomy—feasibility study of a modified ‘artery first’ approach to pancreatic head cancer. Langenbeck's Archives of Surgery. 402:917-923. 2017
- There is no difference in outcome between laparoscopic and open surgery for rectal cancer: a systematic review and meta-analysis on short- and long-term oncologic outcomes. Techniques in Coloproctology. 21:595-604. 2017
- Minimally invasive pancreatic cancer surgery: What is the current evidence?. Medical Oncology. 34:125. 2017
- Microvesicles Contribute to the Bystander Effect of DNA Damage. International Journal of Molecular Sciences. 18:788-788. 2017
- Upregulation of FAM84B during prostate cancer progression. Oncotarget. 8:19218-19235. 2017
- Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. New England Journal of Medicine. 376:417-428. 2017
- Progress towards accurate prediction of overall survival in men with metastatic castration-resistant prostate cancer. Journal of Xiangya Medicine. 2:17-17. 2017
- Enhanced recovery after surgery protocol in oesophageal cancer surgery: Systematic review and meta-analysis. PLoS ONE. 12:e0174382-e0174382. 2017
- Amplification of MUC1 in prostate cancer metastasis and CRPC development. Oncotarget. 7:83115-83133. 2016
- Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. Cancer immunology research. 4:881-892. 2016
- ERAS protocol in laparoscopic surgery for colonic versus rectal carcinoma: are there differences in short-term outcomes?. Medical Oncology. 33:56. 2016
- Laparoscopic colorectal cancer surgery combined with enhanced recovery after surgery protocol (ERAS) reduces the negative impact of sarcopenia on short-term outcomes. European Journal of Surgical Oncology. 42:779-787. 2016
- Phase 2 Study of Acupuncture-Like Transcutaneous Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy. Integrative Cancer Therapies. 15:153-164. 2016
- CYB5D2 displays tumor suppression activities towards cervical cancer. Biochimica et Biophysica Acta: international journal of biochemistry and biophysics. 1862:556-565. 2016
- Cost minimization analysis of laparoscopic surgery for colorectal cancer within the enhanced recovery after surgery (ERAS) protocol: a single-centre, case-matched study.. Wideochirurgia I Inne Techniki Maloinwazyjne. 11:14-21. 2016
- Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. Cancer Research. 76:1603-1614. 2016
- Dataset on the effects of CYB5D2 on the distribution of HeLa cervical cancer cell cycle. Genomics Data. 6:811-816. 2016
- Is ERAS in laparoscopic surgery for colorectal cancer changing risk factors for delayed recovery?. Medical Oncology. 33:25. 2016
- Evaluation of low-dose fractionated radiation therapy as a chemopotentiator of gemcitabine in advanced pancreatic cancer: results from an international multi-institutional phase II trial. Journal of Radiation Oncology. 4:401-409. 2015
- Impact of selective alveolar decortication on bisphosphonate burdened alveolar bone during orthodontic tooth movement. Archives of Oral Biology. 60:1681-1689. 2015
- BMI1 attenuates etoposide-induced G2/M checkpoints via reducing ATM activation. Oncogene. 34:3063-3075. 2015
- Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab.. Journal of Gastrointestinal Oncology. 6:274-279. 2015
- Guidelines on the Use of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Peritoneal Surface Malignancy Arising from Colorectal or Appendiceal Neoplasms. Current Oncology. 22:100-112. 2015
- The Use of the Enhanced Recovery After Surgery (ERAS) Protocol in Patients Undergoing Laparoscopic Surgery for Colorectal Cancer – A Comparative Analysis of Patients Aged above 80 and below 55. Polski Przeglad Chirurgiczny/ Polish Journal of Surgery. 87:565-572. 2015
- SIPL1-facilitated PTEN ubiquitination contributes to its association with PTEN. Cellular Signalling. 26:2749-2756. 2014
- Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. Frontiers in Immunology. 5:191. 2014
- Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology. 2:70-76. 2013
- Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab.. Journal of Clinical Oncology. 31:e14630-e14630. 2013
- Morphologic and functional changes in the temporomandibular joint and stomatognathic system after transmandibular surgery in oral and oropharyngeal cancers: systematic review.. Journal of Otolaryngology - Head and Neck Surgery. 41:345-360. 2012
- A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Investigational New Drugs. 30:1203-1207. 2012
- PET/CT using 18F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. Nuclear Medicine Communications. 33:322-330. 2012
- Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology. 80:411-432. 2011
- A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 68:1199-1206. 2011
- Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. British Journal of Cancer. 105:44-52. 2011
- Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. Journal of Clinical Oncology. 29:1997-2003. 2011
- Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels.. Journal of Clinical Oncology. 29:1-1. 2011
- Zoledronic acid use in cancer patients. Cancer. 117:11-23. 2011
- Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 9:272. 2009
- A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer. Journal of Clinical Oncology. 27:e15634-e15634. 2009
- Preserving Functional Independence in Elderly Patients with Cancer-Associated Bone Disease: The Role of Zoledronic Acid. Aging Health. 5:151-164. 2009
- Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nature Reviews Clinical Oncology. 6:163-174. 2009
- Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treatment Reviews. 34:629-639. 2008
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 113:193-201. 2008
- A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Investigational New Drugs. 26:265-272. 2008
- Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity. Journal of Thoracic Oncology. 3:228-236. 2008
- Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity. Oncologist. 12:1035-1043. 2007
- Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.. Oncologist. 12:1035-1043. 2007
- Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer. Urology. 70:315-319. 2007
- Normalization of bone markers and improved survival during zoledronic acid therapy. Journal of Clinical Oncology. 25:9013-9013. 2007
- Clinical Utility of Biochemical Markers of Bone Metabolism for Improving the Management of Patients with Advanced Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia. 7:346-353. 2007
- Hypoxia-Induced Lactate Dehydrogenase Expression and Tumor Angiogenesis. Clinical Colorectal Cancer. 6:442-446. 2007
- An Optimized Clinical Regimen for the Oncolytic Virus PV701. Clinical Cancer Research. 13:977-985. 2007
- Optimal management of metastatic bone disease. European Journal of Oncology Nursing. 11:S32-S37. 2007
- Optimal management of metastatic bone disease. European Journal of Oncology Nursing. 11:S32-S37. 2007
- A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. Journal of Clinical Oncology. 24:3529-3529. 2006
- Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: Stratified by baseline bone alkaline phosphatase (BALP). Journal of Clinical Oncology. 24:7228-7228. 2006
- Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer. Clinical Cancer Research. 12:3361-3367. 2006
- Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. British Journal of Cancer. 94:1136-1143. 2006
- The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma.. Blood. 106:5192-5192. 2005
- A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Investigational New Drugs. 23:479-484. 2005
- A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. 11:5526-5533. 2005
- Survival-Adjusted Multiple-Event Analysis for the Evaluation of Treatment Effects of Zoledronic Acid in Patients with Bone Metastases from Solid Tumors. Supportive Cancer Therapy. 2:234-240. 2005
- Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome. Journal of Clinical Oncology. 23:532-532. 2005
- The effect of zoledronic acid (Zol) dose and infusion rate on pharmacokinetics (PK), pharmacodynamics (PD), and renal function in patients (pts) with multiple myeloma (MM) or prostate cancer (PC) and bone metastases. Journal of Clinical Oncology. 23:2079-2079. 2005
- Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors. Journal of the National Cancer Institute. 97:59-69. 2005
- A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Investigational New Drugs. 23:165-170. 2005
- The Effect of Increasing Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics, Pharmacodynamics, and Renal Function in Patients with Multiple Myeloma.. Blood. 104:4939-4939. 2004
- A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 22:3109-3109. 2004
- A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 22:3109-3109. 2004
- Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis. Journal of Clinical Oncology. 22:8058-8058. 2004
- Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis. Journal of Clinical Oncology. 22:8058-8058. 2004
- Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 100:36-43. 2004
- Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.. Current Opinion in Molecular Therapeutics. 5:618-624. 2003
- A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.. Clinical Cancer Research. 9:2457-2464. 2003
- Zoledronic acid is superior to pamidronate in patients with breast cancer and bone metastases. Breast. 12:S42-S43. 2003
- Role of octreodite in the management of patients with cancer. Current Oncology. 10:161-179. 2003
- Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical Endpoints. American Journal of Clinical Oncology. 25:S10-S18. 2002
- Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.. American Journal of Clinical Oncology. 25:S10-S18. 2002
- The Use of Zoledronic Acid, a Novel, Highly Potent Bisphosphonate, for the Treatment of Hypercalcemia of Malignancy. Oncologist. 7:481-491. 2002
- Zoledronic acid: An overview of its current and potential benefits in patients with malignancy. Today's Therapeutic Trends. 20:197-219. 2002
- Hypercalcemia of Malignancy. American Journal of Cancer. 1:179-187. 2002
- Use of bisphosphonates in breast cancer metastatic to bone: Compliance with practice guidelines. Current Oncology. 9:7-12. 2002
- Brief infusion of 2 or 4 mg zoledronate is as effective as prolonged infusion of 90 mg pamidronate for osteolytic metastases. Growth Hormone and IGF Research. 2:191-192. 2001
- Methodology for Treatment Evaluation in Patients With Cancer Metastatic to Bone. Journal of the National Cancer Institute. 93:534-538. 2001
- Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program. Seminars in Oncology. 28:17-24. 2001
- Zometa® is effective and well tolerated in the prevention of skeletal related events secondary to metastatic breast cancer treated with hormonal therapy. European Journal of Cancer. 37:S152-S152. 2001
- Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials. Journal of Clinical Oncology. 19:558-567. 2001
- Central venous catheters for infusion therapy in gastrointestinal cancer. A comparative study of tunnelled centrally placed catheters and peripherally inserted central catheters.. Journal of Infusion Nursing. 24:38-47. 2001
- A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Annals of Oncology. 11:1579-1584. 2000
- A Randomized Controlled Trial of Vitamin D Supplementation on Preventing Postmenopausal Bone Loss and Modifying Bone Metabolism Using Identical Twin Pairs. Journal of Bone and Mineral Research. 15:2276-2283. 2000
- Oral bisphosphonates. Cancer. 88:6-14. 2000
- Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. Current Oncology. 7:149-161. 2000
- Placebo-Controlled Trial of 13-cis-Retinoic Acid Activity on Retinoic Acid Receptor-Beta Expression in a Population at High Risk: Implications for Chemoprevention of Lung Cancer. Journal of Clinical Oncology. 17:3546-3552. 1999
- Humanised antibodies for cancer therapy. Part 2: Review of clinical trials with rituximab and trastuzumab. Current Oncology. 6:131-137. 1999
- Humanized antibodies for cancer therapy. Part 1: Humanizing mouse antibodies. Current Oncology. 6:74-77. 1999
- Relevant clinical end points in biphosphonate trials.. Journal of Clinical Oncology. 16:3204-3205. 1998
- Bisphosphonates for bone metastases in breast cancer patients: Trial design issues and evaluation of published studies. Current Oncology. 5:181-187. 1998
- Bone metastases: A review of their pathogenesis. Current Oncology. 5:114-118. 1998
- Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.. Cancer Prevention and Control. 1:241-248. 1997
- Authors' reply. The BMJ. 312:509-510. 1996
- UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. The BMJ. 311:1189-1193. 1995
- Quantitative dot blot analyses of blood‐group‐related antigens in paired normal and malignant human breast tissues. International Journal of Cancer. 50:57-63. 1992
- Recognition of Peptidyl Epitopes by Polymorphic Epithelial Mucin (PEM)-Specific Monoclonal Antibodies. Hybridoma: a journal of molecular immunology and experimental and clinical immunotherapy. 10:595-610. 1991
- Human milk fat globule membrane glycoproteins express blood group-related determinants primarily on mucin-like epithelial membrane antigens and gp70.. IUBMB Life. 22:295-302. 1990
- Breast tumor radioimmunodetection with a 111In-labeled monoclonal antibody (MA5) against a mucin-like antigen.. Cancer Research. 50:927s-931s. 1990
- Patterns of antigen distribution in human carcinomas.. Cancer Research. 50:880s-884s. 1990
- Enhanced Expression and Secretion of an Epithelial Membrane Antigen (MA5) in a Human Mucinous Breast Tumor Line (BT549). Tumor Biology. 11:145-157. 1990
- Breast cancer imaging with mouse monoclonal antibodies. European Journal of Nuclear Medicine and Molecular Imaging. 15:655-660. 1989
- Familial Diffuse Cystic Angiomatosis of Bone. Clinical Orthopaedics and Related Research. 238:211-218. 1989
- Related Glycoproteins from Normal Secretory and Malignant Breast Cells. Tumor Biology. 10:12-22. 1989
- Double antibody radioimmunoassay for monitoring metastatic breast cancer. British Journal of Cancer. 58:362-367. 1988
- Tumor-associated antigens as immunotherapy targets.. Cancer Epidemiology. 12:451-459. 1988
- Cellular heterogeneity in normal and neoplastic human urothelium: A study using murine monoclonal antibodies. British Journal of Cancer. 56:439-444. 1987
- Liposomal incorporation and immunogenicity of carcinoembryonic antigen.. Journal of Biological Response Modifiers. 6:581-586. 1987
- Ultrastructural localization of a breast tumor-associated antigen.. Journal of Histochemistry and Cytochemistry. 35:375-379. 1987
- Monoclonal antibodies to antigens abnormally expressed in breast cancer.. Journal of Histochemistry and Cytochemistry. 35:139-148. 1987
- Expression of common acute lymphoblastic leukemia-associated antigen on germ cell tumor. American Journal of Medicine. 80:1249-1252. 1986
- Fertility considerations in the gynecologic oncology patient.. Oncology Nursing Forum. 13:23-27. 1986
- A phase I?II study of combination therapy with thymidine and cytosine arabinoside. Cancer Chemotherapy and Pharmacology. 11:43-47. 1983
- Relationship between incorporation of 9-beta-D-arabinofuranosyladenine in L 1210 DNA and cytotoxicity.. Cancer Research. 43:2000-2004. 1983
- Effect of high-dose thymidine infusions in patients with mycosis fungoides. Cancer. 48:1513-1516. 1981
- Treatment of central nervous system tumors with methotrexate.. Journal of the National Cancer Institute. 65 Suppl 1:137-140. 1981